歐林生物(688319.SH):收到重組金黃色葡萄球菌疫苗(大腸桿菌)II期臨牀試驗總結報吿
格隆匯12月30日丨歐林生物(688319.SH)公佈,公司與中國人民解放軍陸軍軍醫大學合作研發的重組金黃色葡萄球菌疫苗(大腸桿菌)完成了II期臨牀試驗並於2021年12月29日收到臨牀試驗總結報吿,重組金黃色葡萄球菌疫苗(大腸桿菌)擬用於預防手術後金黃色葡萄球菌感染,屬於預防用生物製品1類。經查詢,截至本公吿披露日,國內外尚無同類產品上市。
依據II期臨牀試驗總結報吿,主要結論如下:重組金黃色葡萄球菌疫苗(大腸桿菌)在中國18-70週歲骨科手術目標人羣中按接種的安全性良好。在首針免後10-14天各免疫程序組特異性抗體水平均達到峯值,免疫原性良好,並且在首針免後42天特異性抗體水平相對基線還處於平台期,在首針免後180天仍然有較高水平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.